2Volm M, Kastel M, Mattem J, et al. Expression of resistance factors(P-gp, glutathione S-transferases π, Topoisomerase Ⅱ) and their interrelationship to proto-oncogene products in renal cancer. Cancer,1993, 71:3981-3987.
5Tsuruo T,Naito M,Tomida A,et al.Molecular targeting therapy of cancer:drug resistance,apoptosis and survival signal.Cancer Sci,2003,94:15-21.
6Fery DR,Traunecker H,Kerr DJ.Clinical trials of P-glycoprorein reversal in solid tumors .Eur J Cancer,1996,32A:1070-1081.
7Krishna R,Mayer LD.Multidrug resistance (MDR) in cancer.Mechanisms,reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs.Eur J Pharm Sci,2000,11:265-283.
8Thomas H,Coley HM.Overcoming multidrug resistance in cancer:an update on the clinical strategy of inhibiting P-glycoprotein.Cancer Control,2003,10:159-165.
9Leonard GD,Fojo T,Bates SE.The role of ABC transporters in clinical practice.Oncologist,2003,8:411-424.
10Zhang JS,Ding J,Tang QM,et al.Synthesis and antitumor activity of novel diterpenequinone salvicine and the analogs.Bioorg Med Chem Lett,1999,9:2731-2736.
